Summary We studied the effects of 5-ethynyluracil (GW776), a potent inactivator of dihydropyrimidine dehydrogenase, on the metabolism of 5-fluorouracil (5-FU), in particular with respect to formation of the toxic compounds fluoroacetate (FAC) and 2-fluoro-3-hydroxypropionic acid (FHPA), using fluorine-19 nuclear magnetic resonance and the isolated perfused rat liver model. Livers were perfused with 5-FU alone at a dose of 15 mg kg-' body weight or with 5-FU + GW776 at doses of 15 mg 5-FU kg-' body weight and 0.5 mg GW776 kg-' body weight injected 1 h before 5-FU. All 5-FU was metabolized in experiments with 5-FU alone whereas unmetabolized 5-FU represented 94% of the fluorinated compounds measured in experiments with 5-FU + GW776. GW776 modulated both the catabolic and the anabolic pathways of 5-FU, the most striking effect being on the degradative pathway. The amount of 5-FU catabolites decreased by a factor of 27 in the presence of GW776. The modulator led to a decrease in a-fluoro-3-alanine (FBAL) formation by a factor of approximately 110, while fluoride ion formation decreased by a factor of approximately 10. By strongly lowering the metabolism of 5-FU into FBAL, GW776 circumvented the transformation of FBAL into toxic FAC and FHPA. 5-FU anabolites increased by a factor of approximately 7 in the presence of GW776. The level of free fluoronucleotides and 5-fluorouridine-5'-diphosphate sugars was increased up to fivefold. No incorporation of 5-FU into RNA could be measured in experiments with 5-FU alone whereas, although low (0.1% of 5-FU injected dose), it was detectable in experiments with 5-FU + GW776. These results suggest that GW776 may be useful for attenuating the not very common but serious cardiotoxic and/or neurotoxic side-effects of 5-FU that are probably due to FBAL metabolites.
adverse reactions include myelosuppression, diarrhoea, vomiting and mucositis. Over the last decade, the number of reports of cardiotoxicity and neurotoxicity attributed to 5-FU has rapidly increased (Anand, 1994; Yeh and Cheng, 1994 ; and references cited therein). The biochemical mechanism underlying these toxic side-effects remains unclear, although it has been postulated that 5-FU, and more precisely its main catabolite ex-fluoro-p-alanine (FBAL) (Mukherjee and Heidelberger, 1960; Bemadou et al, 1985; Heggie et al, 1987; Hull et al, 1988) , might be transformed into fluoroacetate (FAC) (Koenig and Patel, 1970) , a highly cardiotoxic and neurotoxic poison (Pattison and Peters, 1966) . We demonstrated on the isolated perfused rabbit heart model that commercial solutions of 5-FU contain cardiotoxic impurities, namely fluoromalonic acid semialdehyde (FMASAld) and fluoroacetaldehyde (Facet) , that are derived from the degradation of 5-FU in the basic medium required for its solubilization and are metabolized into FAC and 2-fluoro-3-hydroxypropionic acid (FHPA), another cardiotoxic compound (Lemaire et al, 1992 (Lemaire et al, , 1994 . Moreover, we were the first to demonstrate experimentally the biotransformation of pure 5-FU into two new catabolites, FAC and FHPA, in the isolated perfused rat liver (IPRL) model and in rats (Arellano et al, 1994) . This demonstration was extended to the bioconversion of 5-FU into FHPA in humans (Lemaire et al, 1996) . 5-FU metabolism thus progresses further than FBAL, giving rise to two toxic compounds. We therefore proposed that the cardiotoxicity of 5-FU could stem from two sources: (1) degradation products of 5-FU formed over time in basic medium and (2) metabolism of 5-FU itself.
5-Ethynyluracil (GW776) is a potent inactivator of the catabolic pathway of 5-FU acting on dihydropyrimidine dehydrogenase (DPD), the enzyme that converts 5-FU into its first catabolite, 5,6-dihydro-5-fluorouracil (FUH2), thereby preserving 5-FU from its rapid and extensive catabolism (Porter et al, 1992; Baccanari et al, 1993; Spector et al, 1993) . Increases in the 5-FU half-life and in the renal elimination of unchanged 5-FU were recently reported in cancer patients (Khor et al, 1996) . GW776 greatly improved the anti-tumour efficacy, the oral bioavailability and the therapeutic index of 5-FU in animals (Baccanari et al, 1993; Cao et al, 1994) . Moreover, Davis et al (1994) demonstrated that GW776 protected dogs from 5-FU-induced neurotoxicity that could be due to FAC (Koenig and Patel, 1970; Okeda et al, 1984 Okeda et al, , 1990 .
Prevention of formation of toxic compounds from 5-fluorouracil by 5-ethynyluracil 1171 The purpose of the present study was thus to test the effects of GW776 on 5-FU metabolism, in particular with respect to formation of the toxic compounds FAC and FHPA, using fluorine-19 nuclear magnetic resonance ('9F-NMR) and the IPRL model.
MATERIALS AND METHODS IPRL experiments
Livers from male Wistar rats (Iffa Credo, Lyon, France) were isolated and perfused with recirculation of the perfusion medium according to the design originally described by Brauer et al (1951) and modified by Sabouraud et al (1993) . The recirculating perfusate (approximately 180 ml), oxygenated with oxygencarbon dioxide (95%:5%), was a Krebs-Ringer bicarbonate buffer supplemented with glucose (1.3 mM) and bovine serum albumin (0.5%). The perfusate (pH 7.4) was recirculated at a mean flow rate of 10 ml min-1 g-' of liver. The experiments were carried out with solutions of 5-FU prepared immediately before use at a dose of 15 mg kg-' body weight. For experiments with 5-FU alone, the drug was injected into the perfusate after 1 h of liver equilibration, and the experiments (n = 5) were continued for 3 h. For experiments with 5-FU + GW776, 5-FU was injected after 1 h of liver equilibration in the presence of GW776 at a dose of 0.5 mg kg-' body weight , and the experiments (n = 4) were continued for 3 h. A 0.5 M sodium bicarbonate solution was continuously infused into the reservoir to maintain the pH of the perfusate at 7.4. The temperature and pH of the perfusate, portal vein pressure and bile flow were continuously monitored. Bile was collected in preweighed vials at 30-min intervals after the beginning of the liver perfusion. Liver viability was assessed by measuring lactate dehydrogenase (LDH) activity in the perfusate every 30 min.
The pH, vascular resistance, oxygen consumption, LDH activity and bile flow were in the range of the literature values (Sugano et al, 1978; Van Dyke et al, 1983) . The evolution of LDH activity and bile flow are shown in We first checked the purity of the solution of 5-FU injected and demonstrated that it was not chemically transformed in the perfusate bubbled with carbogen for 3 h at 37°C. Indeed, the 19F-NMR spectrum of the perfusion medium after concentration by freeze-drying displayed the single 5-FU peak. We also carried out four control experiments in which the perfusate containing 5-FU at a concentration of 45 mg kg-' body weight (calculated for a mean rat body weight of 400 g) was circulated for 3 h in the perfusion system without liver. The '9F-NMR spectra of these perfusates after concentration only exhibited a strong peak corresponding to British Journal of Cancer (1997) (FBEN) in deuterium oxide doped at saturation with chromium(III) acetylacetonate (Cr(acac)3) to shorten the longitudinal relaxation time (T,) of FBEN. The apparent concentration of the FBEN peak was previously calibrated. Cr(acac)3 (approximately 2.5 mg) was also added to non-concentrated perfusates and bile samples. The areas were determined after the different signals were cut out and weighed.
Fully relaxed spectra were obtained for all media analysed, even when spectra were recorded with a pulse interval as short as 1.4 s and without Cr(acac)3. This was demonstrated for (1) 5-FU, FAC and FHPA in concentrated perfusates recorded with a pulse interval of 1.4 s or 3.4 s without Cr(acac)3 or 10.4 s with Cr(acac)3, (2) 5-FU and FBAL in acid-soluble extracts containing EDTA recorded with a pulse interval of 1.4 s without Cr(acac)3 or 3.4 s with Cr(acac)3. The differences between the values of concentrations thus determined were not more than 10%, which corresponds to the precision of the method (5-10% depending on the concentration; Malet-Martino and Martino, 1992) . The high ionic strength of concentrated perfusates and perchloric acid extracts and the high viscosity of the former medium induced a decrease of the flip angle for a given value of the pulse width (see above) and probably of the T1, leading to an accurate quantification even with a low pulse interval and without Cr(acac)3.
As a step of lyophilization was necessary to measure FHPA and FAC concentrations, we checked the recovery of these two compounds from the lyophilization pellet. Known amounts of FHPA and FAC were added to 450 ml of blank perfusate at concentrations close to those found in the perfusates from rat liver experiments. Three 150-ml fractions were freeze-dried and taken up in water under our normal operating conditions. '9F-NMR spectroscopy showed that only 76 ± 2% and 63 ± 15% of FHPA and FAC, respectively, were recovered. The amounts of FHPA and FAC measured in our experiments were thus underestimated as material remained in the pellet, which was not completely redissolved.
We noticed that the amounts of FBAL (and derivatives) and F-measured in concentrated perfusates were lower than in nonconcentrated perfusates. Of FBAL (and its derivatives), 71 ± 9% was recovered in concentrated perfusates of experiments with 5-FU alone, whereas only 46 ± 10% of F-was recovered in experiments with 5-FU alone and with 5-FU + GW776. This led us to quantify all the 5-FU metabolites in non-concentrated perfusates, except when they were not detected (FBAL and related compounds in 5-FU + GW776 experiments and FAC and FHPA in 5-FU experiments).
Statistical analysis
All results were expressed as means ± s.d. When necessary, statistical significance was determined using Student's t-test. A P-value of < 0.05 was considered to be statistically significant.
RESULTS

Qualitative analysis
IPRL were treated with pure 5-FU at a 'therapeutic' dose of 15 mg kg-' body weight for 3 h with (n = 4) or without (n = 5) a 1-h prior treatment with GW776 at a dose of 0.5 mg kg-' body weight .
A characteristic '9F-NMR spectrum of a non-concentrated perfusate from an IPRL treated with 5-FU alone shows the large signals of 5-FU main catabolites, FBAL at 6 = -112.4 p.p.m. and F-coming from the defluorination of FBAL Porter et al, 1995) at 6 = -43.5 p.p.m. Low signals from a-fluoro-,B-ureidopropionic acid (FUPA) at 6 = -110.7 p.p.m. and CFBAL derived from the interaction of bicarbonate ion with FBAL (Martino et al, 1987) at 6 = -110.9 p.p.m. could also be detected ( Figure IA) . A large signal of 5-FU at 6 = -93.3 p.p.m. and a weak resonance for F-were observed in the '9F-NMR spectrum of a non-concentrated perfusate from an IPRL treated with 5-FU + GW776 (Figure iB) . FUH2 was not observed in any of the experiments.
A characteristic '9F-NMR spectrum of a concentrated perfusate from an IPRL treated with 5-FU alone (Figure 2A) shows the signals of FBAL at 6= -112.6 p.p.m., CFBAL at 6= -111.4 p.p.m. and F-at 6 = -49.0 p.p.m. The differences in the values of chemical shifts in non-concentrated and concentrated perfusates are mainly due to the much higher ionic strength in the concentrated perfusates and to differences in pH (7.6 vs 8.3 respectively).
More CFBAL was present in the concentrated perfusates (compare FBAL increases with pH up to about pH 9 (Martino et al, 1987 Figure 4B ). 
Quantitative analysis Global recovery of 5-FU and its metabolites
The data are presented in 
Proportions of 5-FU and its metabolites
The data are presented in Table 3 . In the experiments with 5-FU alone, FBAL was the main catabolite as it represented 44% of the 5-FU-injected dose whereas F-, present in trace amounts, was the main catabolite (2% of injected dose) in the experiments with 5-FU + GW776.
The main characteristics of the experiments with 5-FU + GW776 are (1) the decrease in FBAL formation by a factor of -110, (2) Repartition of 5-FU and metaboites in the different media analysed (perfusate, bile and liver) The data presented in Table 4 (1997) 76(9), 1170-1180 (Table 2) . Rat livers were thus > 96% inhibited in their ability to catalyse 5-FU degradation. This result is in complete agreement with the study of Baccanari et al (1993) , which reported the same extent of inhibition when DPD activity was measured in liver extracts prepared 1 h or 6 h after rats were treated with a single dose of GW776 (2 mg kg-' p.o.). GW776 led to a decrease in FBAL formation by a factor of-I 10, whereas F formation decreased by a factor of only -10 (Table 3) . L-alanine-glyoxylate aminotransferase II (AlaAT-II) purified from rat liver catalysed the elimination of F from FBAL. The enzyme was not inactivated significantly during dehalogenation of FBAL, and 5-FU was not a substrate (Porter et al, 1995) . To explain our data, one might therefore evoke a slight defluorination of the large amounts of unmetabolized 5-FU remaining during the experiments with 5-FU + GW776 catalysed by another enzyme.
FAC is a highly cardiotoxic and neurotoxic poison (Pattison and Peters, 1966) known to accumulate in the organism (Meldrum and Bignell 1957) . We checked the cardiotoxicity of FHPA on the isolated perfused rabbit heart model at two doses, 0.01 and 1.5 mg kg-'. FHPA did not generate cardiotoxic symptoms at the lowest dose but was highly cardiotoxic on this model at the highest dose (unpublished data). Moreover, FBAL, the precursor of FHPA and FAC (Arellano et al, 1994) , accumulated in rats and was retained up to 8 days in various tissues, mainly liver, heart and brain (Zhang et al, 1992 (Zhang et al, , 1993 . By greatly lowering the metabolization of 5-FU into FBAL, GW776 circumvents the formation of toxic FHPA and FAC (Table 3 ). The present results therefore support the earlier report of Davis et al (1994) . These authors demonstrated that GW776 protected dogs from the neurotoxicity induced by a 26-h continuous infusion of 5-FU at three doses (1.6, 4 or 16 mg kg-' 24 h-') and suggested with others (Koenig and Patel, 1970; Okeda et al, 1984 Okeda et al, , 1990 ) that 5-FU catabolites are responsible for this dose-limiting toxicity in dogs and cats, which are particularly sensitive.
British Journal of Cancer (1997) 76(9), 1170-1180 Prevention of formation of toxic compounds from 5-fluorouracil by 5-ethynyluracil 1179 Also interesting is the effect of GW776 on the anabolic pathway of 5-FU that confers to the drug its cytotoxicity. GW776 increases the therapeutic index of 5-FU in mouse (Baccanari et al, 1993) and rat (Table 3) . No 5-FU incorporated into RNA was observed in the experiments with 5-FU alone whereas the incorporation of 5-FU into RNA, detected as 2'-and 3'FUMP, was low (0.1% of the injected dose) but detectable in the experiments with 5-FU + GW776 (Table 3) . Davis et al (1995) reported that, compared with mice treated with 5-FU alone, GW776 enhanced the incorporation of 5-FJ into RNA in MOPC-315 s.c. tumours of mice.
In conclusion, our study clearly shows that GW776 prevents formation of FBAL and its subsequent metabolism into the toxic FHPA and FAC. GW776 may therefore be useful not only for improving the efficacy of 5-FU but also for attenuating cardiotoxic and/or neurotoxic side-effects of this antitumour agent that may be due to FBAL metabolites. Although these side-effects are not very common, they are severe and may be dose limiting. The combination of GW776 and 5-FU has great clinical potential. GW776 increases the half-life of 5-FU from approximately 14 min to approximately 5 h in humans (Khor et al, 1996) and thereby enables oral dosing to replace the 5-day bolus and the protracted continuous infusion schedules (Baccanari et al, 1993) . Moreover, the dry powder of orally formulated 5-FU presents the advantage of being devoid of cardiotoxic breakdown products found in i.v. solutions (Lemaire et al, 1992) . This combination is currently in intemational phase II clinical trials for breast, pancreatic, colorectal and hepatocellular cancer. IPRL, isolated perfused rat liver; GW776, 5-ethynyluracil; DPD, dihydropyrimidine dehydrogenase; FUH2, 5,6-dihydro-5-fluorouracil; '9F-NMR, fluorine-19 nuclear magnetic resonance; LDH,
